EQL Pharma Management
Management Kriterienprüfungen 2/4
EQL Pharma CEO ist Axel Schorling , ernannt in Aug 2022, hat eine Amtszeit von 3.75 Jahren. Die jährliche Gesamtvergütung beträgt SEK2.90M , bestehend aus 61% Gehalt und 39% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 1.07% der Aktien des Unternehmens, im Wert von SEK8.10M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 0.8 Jahre bzw. 5.8 Jahre.
Wichtige Informationen
Axel Schorling
Geschäftsführender
SEK 2.9m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 61.01% |
| Amtszeit als Geschäftsführer | 3.8yrs |
| Eigentum des Geschäftsführers | 1.1% |
| Durchschnittliche Amtszeit des Managements | less than a year |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 5.8yrs |
Jüngste Management Updates
Recent updates
Analyseartikel • May 14
This Analyst Just Downgraded Their EQL Pharma AB (publ) (STO:EQL) EPS Forecasts
The analyst covering EQL Pharma AB (publ) ( STO:EQL ) delivered a dose of negativity to shareholders today, by making a...Analyseartikel • May 13
EQL Pharma AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models
There's been a major selloff in EQL Pharma AB (publ) ( STO:EQL ) shares in the week since it released its yearly...
Narrativ-Update • Apr 23
EQL: Italian Approval And New Market Entry Will Support Future Upside Potential
Analysts have adjusted their price target on EQL Pharma to SEK 75 from SEK 80, citing updated assumptions for revenue growth, profit margins and future P/E. These changes point to a slightly more conservative outlook on the shares.Narrativ-Update • Apr 09
EQL: Italian Market Entry And Steady Assumptions Will Support Future Upside Potential
Analysts have maintained their SEK price target for EQL Pharma at SEK 80.00, citing consistent assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News EQL's key product Mellozzan, which contains melatonin, has received Marketing Authorization approval from the Italian medicines agency AIFA for use in Italy, through licensing partner Italfarmaco S.p.A. (Key Developments) Mellozzan is indicated for children with ADHD who have sleep difficulties where sleep hygiene measures have not worked, and for short term treatment of jet lag in adults.Narrativ-Update • Mar 26
EQL: Long Term Incentive Program Will Support Strong Future Upside Potential
Analysts keep their SEK 80.00 fair value estimate for EQL Pharma unchanged, reflecting steady assumptions on discount rate, revenue growth, profit margin and future P/E, with no new Street research prompting a shift in the target. What's in the News A special or extraordinary shareholders meeting is scheduled for February 3, 2026, at 13:00 W.Narrativ-Update • Mar 11
EQL: Long Term Incentive Program Will Support Strong Future Upside Potential
Analysts have kept their price target for EQL Pharma steady at SEK 80. This reflects unchanged views on fair value, discount rate, growth and margin assumptions.Narrativ-Update • Feb 24
EQL: Leadership Restructuring And Incentive Plan Will Support Long Term Outlook
Analysts have kept their SEK price target for EQL Pharma unchanged at SEK 80. This reflects stable assumptions on fair value, discount rate, revenue growth, profit margin, and future P/E.Narrativ-Update • Feb 10
EQL: German UTI Prophylaxis Approval Will Support Stronger Long Term Outlook
Analysts have kept their fair value estimate for EQL Pharma unchanged at SEK 80.00. They explain the steady target by slightly different views on discount rate, revenue growth, profit margin and future P/E assumptions rather than any single strong new data point.Narrativ-Update • Jan 27
EQL: German UTI Prophylaxis Launch Will Support Bullish Outlook
Analysts have kept their fair value estimate for EQL Pharma unchanged at SEK 80.00 per share, reflecting consistent assumptions on discount rate, revenue growth, profit margin and future P/E. What's in the News EQL Pharma has called a special or extraordinary shareholders meeting for February 3, 2026, at 13:00 W.Narrativ-Update • Jan 12
EQL: Future UTI Prophylaxis Launch In Germany Will Drive Upside
Analysts have maintained their price target on EQL Pharma at SEK 80.00, citing consistent assumptions for the discount rate, revenue growth, profit margin and future P/E that support keeping the previous fair value assessment unchanged. What's in the News EQL Pharma has called a special/extraordinary shareholders meeting for February 3, 2026, at 13:00 W.Narrativ-Update • Dec 23
EQL: Future UTI Prophylaxis Launch Will Drive Strong Upside Potential
Analysts have modestly adjusted their price target on EQL Pharma upward to SEK 80.0 per share from SEK 80.0 per share, citing unchanged assumptions around discount rate, revenue growth, profit margins, and future valuation multiples that continue to support the company’s current fair value assessment. What's in the News EQL Pharma strengthens and reorganizes its finance function, appointing Allan Sylvest Aasberg as new CFO from early April 2026, while current CFO Anna Jönsson becomes Head of Accounting (Key Developments) The new CFO is tasked with optimizing profitability, capital allocation, forecasting, and parts of investor relations to support a more scalable growth platform (Key Developments) Key product methenamine hippurate receives marketing approval in Germany under the EQL brand Cystohipp, the only registered product of its kind in that market, with launch planned for mid 2026 (Key Developments) Cystohipp targets recurrent urinary tract infections as a non antibiotic prophylactic option, addressing growing demand for alternatives that do not drive antibiotic resistance (Key Developments) EQL issues guidance indicating robust top line expansion, forecasting around 30 percent sales growth for 2024/25 and around 15 percent for 2025/26 (Key Developments) Valuation Changes Fair Value: unchanged at SEK 80.0 per share, indicating no revision to the overall equity valuation.Narrativ-Update • Dec 09
EQL: New Non-Antibiotic UTI Therapy Will Drive Future Upside
Narrative Update on EQL Pharma Analysts have maintained their price target for EQL Pharma at SEK 80.00. This reflects unchanged assumptions on revenue growth, profitability, and valuation multiples despite recent model refinements.Narrativ-Update • Nov 25
EQL: Expanding Market Approvals And New Launches Will Drive Future Upside
Analysts have maintained their price target for EQL Pharma at SEK 80.00. They cite stable fair value estimates supported by slightly improved projections for revenue growth and profit margin.Analyseartikel • Nov 15
EQL Pharma's (STO:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture
Last week's earnings announcement from EQL Pharma AB (publ) ( STO:EQL ) was disappointing to investors, with a sluggish...Narrativ-Update • Nov 06
EQL: Expansion Into New Markets Will Drive Upside In Coming Years
Analysts have lowered their price target for EQL Pharma from SEK 90.00 to SEK 80.00. They cite revised expectations for valuation and a slightly higher discount rate, despite improved forecasts for revenue growth and profit margin.Analyseartikel • Oct 08
EQL Pharma AB (publ) (STO:EQL) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless
EQL Pharma AB (publ) ( STO:EQL ) shareholders that were waiting for something to happen have been dealt a blow with a...Analyseartikel • Sep 27
Do EQL Pharma's (STO:EQL) Earnings Warrant Your Attention?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analyseartikel • Sep 09
Capital Allocation Trends At EQL Pharma (STO:EQL) Aren't Ideal
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...
Narrativ-Update • Aug 16
EQL Pharma's management aiming for 30% Revenue Growth in 5 Years
2025 Q2 update Solid report. Revenue growth in line with expectations.Analyseartikel • May 16
EQL Pharma's (STO:EQL) Earnings Are Of Questionable Quality
EQL Pharma AB (publ) ( STO:EQL ) just reported some strong earnings, and the market reacted accordingly with a healthy...Neues Narrativ • May 11
Pipeline Launches And Global Expansion Will Drive Future Success
Strategic expansions and acquisitions, including Medilink and non-European market entry, are poised to drive significant revenue and profitability growth.Analyseartikel • Mar 12
Here's Why EQL Pharma (STO:EQL) Can Manage Its Debt Responsibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Neues Narrativ • Feb 22
EQL Pharma aiming for 19% Revenue Growth in 5 Years
Recurring Cash Flow: EQL’s core generic product delivers near‐“infinite” cash flow, thanks to its essential role in healthcare.Analyseartikel • Jan 27
The Trend Of High Returns At EQL Pharma (STO:EQL) Has Us Very Interested
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...Analyseartikel • Dec 14
EQL Pharma AB (publ)'s (STO:EQL) P/E Is Still On The Mark Following 37% Share Price Bounce
Despite an already strong run, EQL Pharma AB (publ) ( STO:EQL ) shares have been powering on, with a gain of 37% in the...Analyseartikel • Nov 27
Should You Be Adding EQL Pharma (STO:EQL) To Your Watchlist Today?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analyseartikel • Oct 29
Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher
The EQL Pharma AB (publ) ( STO:EQL ) share price has done very well over the last month, posting an excellent gain of...Analyseartikel • Aug 22
EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings
EQL Pharma AB (publ)'s ( STO:EQL ) stock showed strength, with investors undeterred by its weak earnings report. We...Analyseartikel • Aug 12
Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Jun 13
EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce
The EQL Pharma AB (publ) ( NGM:EQL ) share price has done very well over the last month, posting an excellent gain of...Analyseartikel • May 14
EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Analyseartikel • Feb 21
EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture
EQL Pharma AB (publ)'s ( NGM:EQL ) recent weak earnings report didn't cause a big stock movement. Our analysis suggests...Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | SEK 13m |
| Dec 31 2025 | n/a | n/a | SEK 29m |
| Sep 30 2025 | n/a | n/a | SEK 30m |
| Jun 30 2025 | n/a | n/a | SEK 43m |
| Mar 31 2025 | SEK 3m | SEK 2m | SEK 43m |
| Dec 31 2024 | n/a | n/a | SEK 35m |
| Sep 30 2024 | n/a | n/a | SEK 31m |
| Jun 30 2024 | n/a | n/a | SEK 26m |
| Mar 31 2024 | SEK 2m | SEK 2m | SEK 23m |
Vergütung im Vergleich zum Markt: AxelDie Gesamtvergütung ($USD312.59K) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt Swedish ($USD317.70K).
Entschädigung vs. Einkommen: AxelDie Bezüge der Mitarbeiter sind um mehr als 20 % gestiegen, während die Unternehmensgewinne im vergangenen Jahr um mehr als 20 % gesunken sind.
Geschäftsführer
Axel Schorling (39 yo)
3.8yrs
Amtszeit
SEK 2,903,000
Vergütung
Mr. Axel Schorling has been Independent Director at Gasporox AB (publ) since 2023. Mr. Schörling is President of EQL Pharma AB (publ) from August 15, 2022. He had been the Chief Operating Officer of EQL Ph...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Founder & Chairman | 20.3yrs | SEK 340.00k | keine Daten | |
| President & CEO | 3.8yrs | SEK 2.90m | 1.07% SEK 8.1m | |
| Chief Financial Officer | less than a year | keine Daten | keine Daten | |
| Chief Operating Officer | 3.8yrs | keine Daten | 0.21% SEK 1.6m | |
| Head of Accounting | less than a year | keine Daten | 0.046% SEK 353.5k | |
| Chief Sales Officer | less than a year | keine Daten | keine Daten | |
| Chief Business Development Officer | 3.2yrs | keine Daten | 0.20% SEK 1.5m | |
| CQSCO & Supply Chain Officer | 1.3yrs | keine Daten | keine Daten | |
| Chief Quality | less than a year | keine Daten | keine Daten |
0.8yrs
Durchschnittliche Betriebszugehörigkeit
44yo
Durchschnittliches Alter
Erfahrenes Management: EQLDas Führungsteam des Unternehmens gilt nicht als erfahren ( 0.8 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Founder & Chairman | 20.3yrs | SEK 340.00k | keine Daten | |
| Independent Director | 6.3yrs | SEK 180.00k | 0.0085% SEK 64.4k | |
| Independent Director | 7.8yrs | SEK 200.00k | 0.034% SEK 257.5k | |
| Independent Director | 5.3yrs | SEK 170.00k | 0.034% SEK 257.5k | |
| Director | 1.8yrs | SEK 150.00k | keine Daten | |
| Independent Director | less than a year | keine Daten | keine Daten |
5.8yrs
Durchschnittliche Betriebszugehörigkeit
58yo
Durchschnittliches Alter
Erfahrener Vorstand: EQLDie Vorstandsmitglieder gelten als erfahren (5.8 Jahre durchschnittliche Amtszeit).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/27 14:24 |
| Aktienkurs zum Tagesende | 2026/05/27 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2026/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
EQL Pharma AB (publ) wird von 1 Analysten beobachtet. 1 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Erik Hultgård | DNB Carnegie Commissioned Research |